Over the last two days the FDA’s Pharmacy Compounding Advisory Committee (PCAC) has been reviewing seven peptides for potential inclusion on the 503A Bulk Drug Substances List, and has recommended advancing six of the compounds discussed. That recommendation now goes to the FDA for formal consideration.
We’re grateful to Secretary Kennedy and President Trump for allowing this important conversation regarding peptides to take place, and look forward to the FDA's formal decision on all peptides under review. We remain committed to building the care system this category deserves.
